This phenomenon, in which lymphoma patients undergoing B-cell depleting therapy demonstrate CD8 T-cell responses with frequencies and magnitudes equivalent to healthy controls, emphasizes the crucial potential for powerful cellular immune responses despite a decreased serological profile (40, 41). This evidence concerns the gene CD8A and lymphoma.